3,257 reports of this reaction
3.3% of all CARBIDOPA AND LEVODOPA reports
#4 most reported adverse reaction
TREMOR is the #4 most commonly reported adverse reaction for CARBIDOPA AND LEVODOPA, manufactured by Amneal Pharmaceuticals LLC. There are 3,257 FDA adverse event reports linking CARBIDOPA AND LEVODOPA to TREMOR. This represents approximately 3.3% of all 97,592 adverse event reports for this drug.
Patients taking CARBIDOPA AND LEVODOPA who experience tremor should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREMOR is moderately reported among CARBIDOPA AND LEVODOPA users, representing a notable but not dominant share of adverse events.
In addition to tremor, the following adverse reactions have been reported for CARBIDOPA AND LEVODOPA:
The following drugs have also been linked to tremor in FDA adverse event reports:
TREMOR has been reported as an adverse event in 3,257 FDA reports for CARBIDOPA AND LEVODOPA. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREMOR accounts for approximately 3.3% of all adverse event reports for CARBIDOPA AND LEVODOPA, making it a notable side effect.
If you experience tremor while taking CARBIDOPA AND LEVODOPA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.